Radiation therapy may be safely omitted for patients with primary mediastinal B-cell lymphoma (PMBCL) who achieved a complete metabolic response after immunochemotherapy.
Ruxolitinib cream is under review at the US Food and Drug Administration for treating vitiligo in patients ages 12 years and older; the agency is expected to make a decision by July 18.